Editorial: Cancer treatment-related cardiovascular disease - real world data in cardio-oncology

Editorial on the Research TopicCancer treatment-related cardiovascular disease -real world data in cardio-oncology Modern anti-cancer therapies have revolutionized cancer treatment.With improving outcomes and survival and cure rates, the significance of cancer treatment-related cardiovascular disease (CTRCD) or toxicity (CTR-CVT) is also being realized (1, 2).The crux of cardio-oncology is to understand such interactions better, to reduce their morbidity and mortality, and to develop protocols and guidelines to manage CTRCD through collaborative efforts in the clinic and research (2, 3).The Global Cardio-oncology Registry has initiated multinational collaboration and has prioritized research on CTRCD in the setting of breast cancer, hematological cancers, and immune-checkpoint inhibitors (ICI) (4).The spectrum of CTRCD, however, is not limited to these alone.Recently published ESC guidelines focus on the definition and management of the entire spectrum of CTRCD (5).Multiple myeloma is mostly diagnosed in elderly patients with pre-existing cardiovascular (CV) comorbidities (5, 6).Anti-myeloma combination therapy, including immunomodulators (IMiDs), dexamethasone, proteasome inhibitors, and monoclonal antibodies (MABs), has demonstrated an increased risk of serious cardiovascular adverse events (CVAEs), necessitating simple and quick clinical tools for risk stratification (5).Yuan et al., in a retrospective study of 253 newly diagnosed multiple myeloma (NDMM) patients, developed and validated a risk score prognostic and predictive model for CVAEs in this patient population.Patients were divided into training and validation cohorts randomly.Univariate and multivariate analysis identified three independent factors associated with CVAEsage > 61 years, high baseline blood pressure (BP), and left ventricular (LV) hypertrophy.Age was assigned 2 points and others 1 point each toFrontiers in Oncology frontiersin.org01